Alzheimer’s Trial Recruitment Innovation Lab

Alzheimer’s Trial Recruitment Innovation Lab

The Alzheimer’s Trial Recruitment Innovation Lab (ATRIL) seeks to diversify participant recruitment and accelerate the process of enrolling a representative population in preclinical and prodromal Alzheimer’s clinical trials through evidence-based science, community engagement and training. ATRIL tests novel recruitment methods that shift the focus from traditional research and healthcare settings towards community-based activities that reach diverse participants who are eligible for earlier intervention trials.

Program Leadership

Rema Raman, PhD

Director, ATRIL
Professor of Neurology, USC Keck School of Medicine
Director, Section of Biostatistics & Section of Participant Recruitment & Retention,
Alzheimer’s Therapeutic Research Institute

Jevay Grooms, PhD

Nonresident Senior Scholar, USC Schaeffer Institute
2023 – 2024 USC AD/ADRD RCMAR Scientist, USC Schaeffer Center
Co-Director, ATRIL
Associate Professor of Economics and Co-Director, Center for an Equitable Economy and Sustainable Society, Howard University

ATRIL Principal Investigators and Management

Research Projects

ATRIL is a collaboration between the USC Schaeffer Center for Health Policy & Economics, the Alzheimer’s Therapeutic Research Institute and Howard University. The Center is part of the American Heart Association’s Strategically-Focused Research Network on the Science of Diversity in Clinical Trials.
ATRIL’s research projects build on an online participant registry, the APT Webstudy, to engage and recruit diverse participants for potential enrollment into a trial-ready cohort for immediate access to ongoing Alzheimer’s clinical trials. The FIND-AD project evaluates the impact of using financial incentives in a health system or community setting on the enrollment of underrepresented groups into the registry. The REACH-AD project evaluates innovative, remote, and unsupervised digital cognitive instruments for early detection of change consistent with preclinical Alzheimer’s disease in the registry.

ATRIL Fellows